On October 28, 2024, Lucent Diagnostics, a brand of Quanterix Corporation, introduced LucentAD Complete, a new multi-marker blood test for Alzheimer’s Disease (AD). This test is designed to aid in detecting AD in a broader range of patients.
The LucentAD Complete test utilizes a proprietary algorithm to score five AD-related biomarkers, including p-Tau 217, Aβ42/40, NfL, and GFAP. Data from over 1,000 patients across three independent clinical cohorts showed it achieved over 90% accuracy in amyloid classification.
This multi-marker approach significantly reduces the 'intermediate zone' of uncertainty by threefold compared to single-marker tests, providing more definitive results for patients. The test development was funded by the Alzheimer’s Drug Discovery Foundation's Diagnostics Accelerator.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.